The short version of immunomodulator fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-01 and is reviewed periodically as new material appears.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
In the past, fishing vessels were restricted in range by the simple consideration that the catch must be returned to port before it spoils and becomes worthless. The development of refrigeration and freezing technologies transformed the commercial fishing industry: fishing vessels could be larger, spending more time away from port and therefore accessing fish stocks at a much greater distance. Refrigeration and freezing also allow the catch to be distributed to markets further inland, reaching customers who previously would have had access only to dried or salted sea fish. Canning, developed during the 19th century, has also had a significant impact on fishing by allowing seasonal catches of fish that are possibly far from large centres of population to be exploited. For example: canned sardines. Preservation techniques are needed to prevent fish spoilage and lengthen shelf life. They are designed to inhibit the activity of spoilage bacteria and the metabolic changes that result in the loss of fish quality. Spoilage bacteria are the specific bacteria that produce the unpleasant odours and flavours associated with spoiled fish. Fish normally host many bacteria that are not spoilage bacteria, and most of the bacteria present on spoiled fish played no role in the spoilage. To flourish, bacteria need the right temperature, sufficient water and oxygen, and surroundings that are not too acidic. Preservation techniques work by interrupting one or more of these needs. Preservation techniques can be classified as follows.
Neutrophils display highly directional amoeboid motility in infected footpad and phalanges. Intravital imaging was performed in the footpad path of LysM-eGFP mice 20 minutes after infection with Listeria monocytogenes.
==== Metabolic acidosis and potassium ==== The bicarbonate content should ideally be between 17 and 22 mEq/L. Sodium bicarbonate or potassium citrate is administered for buffering, whereby the latter also compensates for any existing potassium deficiency. A diet rich in potassium and magnesium is recommended and is already used in most commercial kidney diets. Potassium gluconate can also be used to compensate for a potassium deficiency, but potassium chloride is usually poorly accepted by cats and often causes gastrointestinal disorders. The restriction of renal excretion in stage IV, ACE inhibitors or aldosterone deficiency due to renin deficiency can also lead to hyperkalemia, which is why potassium levels must be checked regularly and a low-potassium diet may also need to be used.
Vopratelimab (JTX-4014) by Jounce Therapeutics As of 2020 entered Phase I trial Spartalizumab (PDR001) is a PD-1 inhibitor developed by Novartis to treat both solid tumors and lymphomas, which as of 2018 has entered Phase III trials. Camrelizumab (SHR1210) is an anti-PD-1 monoclonal antibody introduced by Jiangsu HengRui Medicine Co., Ltd. that recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. Sintilimab (IBI308), a human anti-PD-1 antibody developed by Innovent Biologics and Eli Lilly for patients with non-small cell lung cancer (NSCLC). INCMGA00012 (MGA012) is a humanized IgG4 monoclonal antibody developed by Incyte and MacroGenics. AMP-224 by AstraZeneca/MedImmune and GlaxoSmithKline AMP-514 (MEDI0680) by AstraZeneca Acrixolimab (YBL-006) by Y-Biologics Sasanlimab by Pfizer
In 1723 Moritz Anton Cappeller published Prodromus Crystallographiae, the first treatise on crystal shapes. The introduction of the term crystallography is attributed to Cappeller. In 1735 Carl Linnaeus, who is known for his system of classification of biological species in his Systema Naturae, also classified minerals and stated that "their transparency is derived from their atomical construction". In 1745 Guillaume-François Rouelle carried out a microscopic analysis of sea salt and proposed that the crystals were composed of cubic particles. In 1758 Roger Joseph Boscovich published his atomic theory which stated that particles of matter were linked by attractive and repulsive forces and that the solid so formed was compressible rather than rigid; this would become relevant in the 19th century when Haüy theorised that crystals were constructed from identical units stacked up without spaces. The idea of a polyhedral molecular unit of crystal structure was promoted by Pierre-Joseph Macquer in his handbook Dictionnaire de chymie of 1766. In 1767 Christian Friedrich Gotthard Westfeld wrote that calcite crystals could be built from rhombohedra. In 1773 Torbern Bergman, a leader in the field of chemical analysis, described the crystal forms of calcite and stated that all the forms could be built up from the cleavage rhombohedron. Bergman developed a classification of minerals based on chemical characteristics (extending the work of Linnaeus), with subclasses organized by their external shapes, and defined seven primary crystal forms. With Jean-Baptiste L.
Sources: en.wikipedia.org
Thus, when the neuron is at a depolarized membrane potential, polyamines will block the AMPAR channel more strongly, preventing the flux of potassium ions through the channel pore. GluA2-lacking AMPARs are, thus, said to have an inwardly rectifying I/V curve, which means that they pass less outward current than inward current at equivalent distance from the reversal potential. Calcium permeable AMPARs are found typically early during postnatal development on neocortical pyramidal neurons, some interneurons, or in dopamine neurons of the ventral tegmental area after the exposure to an addictive drug. Alongside RNA editing, alternative splicing allows a range of functional AMPA receptor subunits beyond what is encoded in the genome. In other words, although one gene (GRIA1–GRIA4) is encoded for each subunit (GluA1–GluA4), splicing after transcription from DNA allows some exons to be translated interchangeably, leading to several functionally different subunits from each gene. The flip/flop sequence is one such interchangeable exon. A 38-amino acid sequence found prior to (i.e., before the N-terminus of) the fourth membranous domain in all four AMPAR subunits, it determines the speed of desensitization of the receptor and also the speed at which the receptor is resensitized and the rate of channel closing. The flip form is present in prenatal AMPA receptors and gives a sustained current in response to glutamate activation.
== Analysis == The analysis of YTXs is necessary because of the possible health risks and the limits put in place by the European Commission directive. It is complex due to the large number of YTX analogues that can be present in the sample. Analysis is also problematic because YTXs have similar properties to other lipophilic toxins present in the samples, so methods can be subject to false negative or false positive results due to sample interferences. Several experimental techniques have been developed to detect YTXs, each offering varying levels of selectivity and sensitivity, whilst having numerous advantages and disadvantages.
StoreDot is a developer of lithium-ion (Li-ion) batteries for electric vehicles founded in 2012 by Doron Myersdorf, Simon Litsyn, and Gil Rosenman. It is based in Herzliya, Israel. The company was founded around developing peptide-based mobile phone displays and data storage. The company reported it was ready to commercially release these products: peptide-based displays by 2016; peptide-based batteries for mobile phones that fully charge in 30 seconds by 2016; germanium-based mobile phone batteries by 2019; electric car and aerial drone batteries that fully charge in five minutes by 2020; scooter batteries that fully charge in under five minutes by 2021; and silicon-graphite-electrode batteries in 2025. None of the aforementioned products have been commercially released as of February 2026. Financial journalists estimated in February 2026 that StoreDot has funding for a few more months of operations. StoreDot stated in 2026 it needs two more years of development in order to commercialize its product.
== Opinion polls == Polling on voting intention was published from May 2023 onwards, most regularly by the National Institute of Development Administration (NIDA), and increased in frequency after the dissolution of the House in December 2025. The final NIDA survey, conducted between 23 and 27 January 2026 among 2,500 respondents, placed the People's Party on 34.2 per cent and Bhumjaithai on 22.6 per cent. The People's Party did lead the party-list vote at the election, taking 30.56 per cent to Bhumjaithai's 17.90 per cent, though Bhumjaithai won far more seats through the constituencies.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.